1573-P: Inverse Association between Serum High-Molecular-Weight Adiponectin Level and Proinsulin Level in a General Japanese Population: DOSANCO Health Study
Authors: NAKAMURA AKINOBU , MIYOSHI HIDEAKI , UKAWA SHIGEKAZU , NAKAMURA KOSHI , NAKAGAWA TAKAFUMI , TERAUCHI YASUO , TAMAKOSHI AKIKO , ATSUMI TATSUYA 
Published: June 2020

Background and Aims: The nature of the relationship between serum adiponectin and pancreatic beta-cell function remains controversial. In this community-based study, we investigated the association between serum high-molecular-weight (HMV) adiponectin and proinsulin levels in a general Japanese population.

Methods: In this cross-sectional study, we analyzed data for residents aged between 35 and 79 years in a rural community in Hokkaido, Japan. A total of 488 participants (53.9% women) without insulin and/or oral hypoglycemic agents were enrolled. Univariate linear regression analysis was performed to examine the association between ln-transformed serum HMV adiponectin and ln-transformed proinsulin levels. Multiple linear regression analysis was used to calculate coefficients after adjusting for age and sex. Estimates included partial regression coefficient (β) and corresponding 95% CI.

Results: Serum HMW adiponectin was significantly inversely associated with proinsulin by univariate linear regression analysis (β: −0.36; 95% CI: −0.44 to −0.29). Multiple linear regression analysis showed that HMW adiponectin was inversely associated with proinsulin after adjusting for age and sex (β: −0.37; 95% CI: −0.46 to −0.28). When the participants were classified into two groups by median BMI, serum insulin or HOMA-IR, similar inverse associations were observed after adjusting for age and sex irrespective of the levels of each factor. Furthermore, these inverse associations were observed in both participants with and without diabetes.

Conclusions: HMW adiponectin level was inversely associated with proinsulin level in a general Japanese population. HMW adiponectin may have a protective effect on beta-cell function.

Disclosure

A. Nakamura: None. H. Miyoshi: Research Support; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K.K., Novo Nordisk Inc., Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd. Speaker’s Bureau; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K.K., Kowa Company, Ltd., MDS CO. LTD., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Sumitomo Dainippon Pharma Co., Ltd. Other Relationship; Self; Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., Kowa Company, Ltd., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd. S. Ukawa: None. K. Nakamura: None. T. Nakagawa: None. Y. Terauchi: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K.K., Novo Nordisk A/S, Sanofi. Consultant; Self; Astellas Pharma Inc. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K.K., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Ono Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited. Speaker’s Bureau; Self; Astellas Pharma Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K.K., Kowa Company, Ltd., Medscape, Medtronic, Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Ono Pharmaceutical Co., Ltd., Sanofi, Sanwa Kagaku Kenkyusho, Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Terumo Medical Corporation. A. Tamakoshi: None. T. Atsumi: Consultant; Self; Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline plc., Pfizer Inc., UCB Japan Co. Ltd. Speaker’s Bureau; Self; AbbVie Inc., Alexion Pharmaceuticals, Inc., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Eisai Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, Inc., Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Takeda Pharmaceutical Company Limited, UCB Japan Co. Ltd.

Funding

Integration Research for Agriculture and Interdisciplinary Fields (538261); Japan Society for the Promotion of Science (JP26670322)